Medical Devices Startups

Incanthera develops and commercializes therapeutics derived from the Institute of Cancer Therapeutics in Bradford. The company operates a direct-to-consumer model with a global network of influencers and ambassadors, targeting multi-billion dollar markets outside the US.

1 investor

Incentive Incubator is a seed-stage incubator in Israel that screens early-stage companies and provides support through a network of business, technology, and strategic experts. The organization operates as the seed arm of Peregrine Ventures and co-invests with other venture capital firms.

1 investor

Incepto provides a curated platform of AI tools integrated into radiology workflows for European healthcare institutions. The company guides radiologists and hospitals through AI solution selection, integration, and optimization to improve diagnostic accuracy and operational efficiency.

1 investor

Incisive Genetics develops non-viral gene editing therapeutics using proprietary lipid nanoparticle delivery technology to treat genetic diseases by editing genes directly in target tissues. The company focuses initially on Huntington's disease and is advancing toward human clinical trials.

1 investor

InCurA develops medical devices focused on bleeding control and hemostatic solutions for surgical, dental, and emergency applications, with manufacturing and distribution across the MENA region and GCC countries. The company uses machine learning-optimized R&D to identify medical needs and commercialize biomedical innovations in markets with access gaps.

1 investor

Incus provides audio processing algorithms for Bluetooth earphones, including echo cancellation, sound localization, noise reduction, and wind noise suppression to improve audio quality in complex environments. The company's solutions are embedded in TWS (true wireless) earbuds used by major manufacturers.

1 investor

Incyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas. The company focuses on bringing treatments to patients across multiple disease categories.

1 investor

Indee Labs develops Hydropore™, a non-viral microfluidic technology for delivering molecules, nucleic acids, proteins, and gene-editing complexes into immune cells for engineered cell therapy research and manufacturing. The platform enables rapid production of high-quality T-cell immunotherapies and other cell therapies with preserved cell function.

1 investor

InDevR develops off-the-shelf and custom analytical testing solutions, including its VaxArray microarray platform and multiplex immunoassays, for the development, optimization, and manufacturing of mRNA-, protein-, polysaccharide, conjugate, and viral vector-based vaccines. It serves vaccine developers and manufacturers with GMP- and 21 CFR Part 11-compliant assays used across R&D, clinical trials, and release testing.

1 investor

Indi Molecular develops small-molecule oncology therapeutics based on protein-catalyzed capture agents (PCCs) created through click chemistry, a synthetic process developed in collaboration with Caltech. The company focuses on drug candidates targeting ovarian and pancreatic cancer.

1 investor

INDIBA is a medtech company that develops radiofrequency and laser-based therapies for aesthetics, rehabilitation, sports medicine, intimate health, and animal health. The company serves clinics, medical practices, and healthcare providers across multiple therapeutic sectors.

1 investor

Indigo is developing an implantable continuous multi-metabolite monitoring (CMM) sensor based on silicon photonics that measures metabolites such as glucose, ketone, and lactate in real time, with data shown via a smartphone app. The device targets chronic disease management, initially diabetes, with potential applications in chronic kidney disease, oncology, cardiovascular disease, and athletic performance.

1 investor

Indira IVF provides in-vitro fertilization treatment services across a network of clinics in India, focused on increasing awareness and accessibility of fertility treatments. The company operates through standardized clinical protocols and trained gynecologists to deliver consistent outcomes across its clinics.

1 investor

IndiTreat is a CE IVD-marked functional drug sensitivity test that uses patient-derived tumor organoids to guide personalized treatment decisions for metastatic colorectal cancer (mCRC) patients. It is aimed at healthcare professionals and oncologists as a complement to traditional biomarker testing.

1 investor

Indivi is a medical technology company developing tools for precision and personalised medicine in neuroscience research and development, including Bring Your Own Device (BYOD) technology. It collaborates with RC2NB to characterise disease processes and support personalised disease management for people affected by MS and other neuroimmune and neurodegenerative diseases.

1 investor

Infius Health manufactures in-vitro diagnostic kits that automate manual medical testing procedures. The company serves healthcare providers and laboratories requiring diagnostic solutions.

1 investor

Inflamalps is a biopharmaceutical company discovering anti-inflammatory and anti-microbial molecules, with its lead candidate INF101 targeting dry eye disease in ophthalmology. Since 2020 it has run a drug discovery program for novel anti-microbial molecules in partnership with academic and CRO partners across Europe and New Zealand.

1 investor

InformedDNA applies genetics expertise and technology to deliver genomics insights and services such as telegenetic counseling for payors, healthcare providers, and patients across the US. It operates in the digital health and genomics space, supporting clinical decisions around screening, diagnosis, and treatment.

1 investor

Informuta provides predictive infection intelligence tools that forecast antibiotic resistance risk to help clinicians prevent treatment failures and optimize antibiotic prescribing decisions. The company serves healthcare providers and infectious disease practitioners with AI-driven diagnostics and bacterial evolutionary analytics.

1 investor

Infraredx develops intravascular imaging technology that combines high-resolution structural imaging with plaque compositional analysis to inform vascular treatment decisions. The company operates in the medical device sector and is a U.S. subsidiary within Nipro Corporation's Vascular Division.

1 investor

InfuSense develops an electrochemical sensing technology platform that detects analytes at sub-therapeutic levels, delivering sample analysis results within minutes. The portable device is designed to bring laboratory-scale testing capabilities into a handheld form factor.

1 investor

Infusion Innovations develops medical devices and intelligent systems for home infusion therapies, serving healthcare providers in Australia/New Zealand, North America, and Europe. The company addresses complex health conditions including rheumatology, gastrointestinal disorders, infectious diseases, cancer, and immune deficiencies through condition-specific technologies, clinical management tools, and data analytics.

1 investor

Inhalis Therapeutics researches and develops inhaled treatments for Idiopathic Pulmonary Fibrosis and other life-threatening diseases, using inhalation delivery technology. It focuses on providing safer and more effective therapy options for patients.

1 investor

InkVivo Technologies develops polymer-based drug delivery platforms (GARD/gastroretentive and SHEALD/injectable) for controlled, localized, and sustained release of small molecules and biologics. An ETH Zurich spin-off, it works with pharmaceutical and nutraceutical partners to improve bioavailability and patient adherence, with programs targeting iron deficiency anemia and neurodegenerative diseases.

1 investor